Your browser doesn't support javascript.
loading
Loss of Tet1-Associated 5-Hydroxymethylcytosine Is Concomitant with Aberrant Promoter Hypermethylation in Liver Cancer.
Thomson, John P; Ottaviano, Raffaele; Unterberger, Elif B; Lempiäinen, Harri; Muller, Arne; Terranova, Remi; Illingworth, Robert S; Webb, Shaun; Kerr, Alastair R W; Lyall, Marcus J; Drake, Amanda J; Wolf, C Roland; Moggs, Jonathan G; Schwarz, Michael; Meehan, Richard R.
Afiliação
  • Thomson JP; MRC Human Genetics Unit at the Institute of Genetics and Molecular Medicine at the University of Edinburgh, Edinburgh, United Kingdom.
  • Ottaviano R; MRC Human Genetics Unit at the Institute of Genetics and Molecular Medicine at the University of Edinburgh, Edinburgh, United Kingdom.
  • Unterberger EB; Department of Toxicology, Institute of Experimental and Clinical Pharmacology and Toxicology, University of Tübingen, Tübingen, Germany.
  • Lempiäinen H; Preclinical Safety, Novartis Institutes for Biomedical Research, Basel, Switzerland.
  • Muller A; Preclinical Safety, Novartis Institutes for Biomedical Research, Basel, Switzerland.
  • Terranova R; Preclinical Safety, Novartis Institutes for Biomedical Research, Basel, Switzerland.
  • Illingworth RS; MRC Human Genetics Unit at the Institute of Genetics and Molecular Medicine at the University of Edinburgh, Edinburgh, United Kingdom.
  • Webb S; Wellcome Trust Centre for Cell Biology, University of Edinburgh, Edinburgh, United Kingdom.
  • Kerr AR; Wellcome Trust Centre for Cell Biology, University of Edinburgh, Edinburgh, United Kingdom.
  • Lyall MJ; University/BHF Centre for Cardiovascular Science, University of Edinburgh, Edinburgh, United Kingdom.
  • Drake AJ; University/BHF Centre for Cardiovascular Science, University of Edinburgh, Edinburgh, United Kingdom.
  • Wolf CR; Medical Research Institute, University of Dundee, Ninewells Hospital & Medical School, Dundee, United Kingdom.
  • Moggs JG; Preclinical Safety, Novartis Institutes for Biomedical Research, Basel, Switzerland.
  • Schwarz M; Department of Toxicology, Institute of Experimental and Clinical Pharmacology and Toxicology, University of Tübingen, Tübingen, Germany. Richard.Meehan@igmm.ed.ac.uk michael.schwarz@uni-tuebingen.de.
  • Meehan RR; MRC Human Genetics Unit at the Institute of Genetics and Molecular Medicine at the University of Edinburgh, Edinburgh, United Kingdom. Richard.Meehan@igmm.ed.ac.uk michael.schwarz@uni-tuebingen.de.
Cancer Res ; 76(10): 3097-108, 2016 05 15.
Article em En | MEDLINE | ID: mdl-27197233
ABSTRACT
Aberrant hypermethylation of CpG islands (CGI) in human tumors occurs predominantly at repressed genes in the host tissue, but the preceding events driving this phenomenon are poorly understood. In this study, we temporally tracked epigenetic and transcriptomic perturbations that occur in a mouse model of liver carcinogenesis. Hypermethylated CGI events in the model were predicted by enrichment of the DNA modification 5-hydroxymethylcytosine (5hmC) and the histone H3 modification H3K27me3 at silenced promoters in the host tissue. During cancer progression, selected CGIs underwent hypo-hydroxymethylation prior to hypermethylation, while retaining H3K27me3. In livers from mice deficient in Tet1, a tumor suppressor involved in cytosine demethylation, we observed a similar loss of promoter core 5hmC, suggesting that reduced Tet1 activity at CGI may contribute to epigenetic dysregulation during hepatocarcinogenesis. Consistent with this possibility, mouse liver tumors exhibited reduced Tet1 protein levels. Similar to humans, DNA methylation changes at CGI in mice did not appear to be direct drivers of hepatocellular carcinoma progression, rather, dynamic changes in H3K27me3 promoter deposition correlated strongly with tumor-specific activation and repression of transcription. Overall, our results suggest that loss of promoter-associated 5hmC in liver tumors licenses reprograming of DNA methylation at silent CGI during progression. Cancer Res; 76(10); 3097-108. ©2016 AACR.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Proteínas Proto-Oncogênicas / Regiões Promotoras Genéticas / Ilhas de CpG / Metilação de DNA / 5-Metilcitosina / Proteínas de Ligação a DNA / Neoplasias Hepáticas Experimentais Tipo de estudo: Prognostic_studies / Risk_factors_studies Limite: Animals Idioma: En Ano de publicação: 2016 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Proteínas Proto-Oncogênicas / Regiões Promotoras Genéticas / Ilhas de CpG / Metilação de DNA / 5-Metilcitosina / Proteínas de Ligação a DNA / Neoplasias Hepáticas Experimentais Tipo de estudo: Prognostic_studies / Risk_factors_studies Limite: Animals Idioma: En Ano de publicação: 2016 Tipo de documento: Article